Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Affigen
AddedFeb 15, 2024
UpdatedJun 18, 2026
Affigen

Affigen

Series A

St. Louis startup developing targeted therapies for tumor identification and treatment.

HQ
St. Louis, MO, US
Founded
2016
Overview
Compare
Fundraising
Employees
Website

Affigen, founded in St. Louis, focuses on developing targeted therapies for the identification and treatment of tumors. The company's core mission is to revolutionize cancer treatment by creating drugs that specifically target molecules in cancerous tumors, thereby improving the precision and efficacy of cancer therapies. Affigen aims to address the unmet needs in oncology by providing innovative solutions that enhance patient outcomes and quality of life.

Notable figures associated with Affigen include leading oncologists and researchers who contribute to the development of their groundbreaking therapies. The company has attracted significant investment from venture capital firms specializing in biotech and healthcare innovations. Key achievements include successful preclinical trials demonstrating the efficacy of their targeted therapies. Affigen's impact lies in its potential to transform cancer treatment paradigms, offering hope to patients with difficult-to-treat tumors.

Affigen - Similar Companies

AffaMed Therapeutics logo

AffaMed Therapeutics

affamed.com

A2 Biotherapeutics logo

A2 Biotherapeutics

a2bio.com

Signet Therapeutics logo

Signet Therapeutics

OncoResponse logo

OncoResponse

Camino Pharma logo

Camino Pharma

caminopharma.com

On Target Laboratories logo

On Target Laboratories

Affini-T Therapeutics logo

Affini-T Therapeutics

affinittx.com

TumorGen logo

TumorGen

tumorgen.net

AffyImmune Therapeutics logo

AffyImmune Therapeutics

affyimmune.com

Affinia Therapeutics logo

Affinia Therapeutics

affiniatx.com

Geneos Therapeutics logo

Geneos Therapeutics

geneostx.com

Affinity Therapeutics logo

Affinity Therapeutics

Oncofactor logo

Oncofactor

oncofactor.com

Neoantigenics logo

Neoantigenics

Alphyn Biologics logo

Alphyn Biologics

Affigen - Quick Facts

Who are Affigen's competitors?

Companies similar to Affigen include AffaMed Therapeutics, A2 Biotherapeutics, Signet Therapeutics and OncoResponse.

When was Affigen founded?

Affigen was founded in 2016.

Where is Affigen's headquarters located?

Affigen's headquarters is located in St. Louis, MO, US.

When was Affigen's last funding round?

Affigen's most recent funding round was for $17M (USD) in February 2017.

How much has Affigen raised to-date?

As of Feb 21, 2017, Affigen has raised a total of $17M (USD).

How many employees does Affigen have?

Affigen has 6 employees as of Feb 4, 2024.

Affigen - Classification

Ownership
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Cancer Therapies
Tags
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 4 more industry codes
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified